PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data.
完整摘要 · 中文译文
背景:多项随机对照试验(RCT)已确立PD-1/PD-L1抑制剂为三阴性乳腺癌(TNBC)的标准治疗,但既往荟萃分析缺乏完整的情境覆盖、成熟的长期生存数据以及对化疗骨架影响的量化——鉴于IMpassion130(白蛋白结合型紫杉醇,阳性)与IMpassion131(紫杉醇,阴性)的对比,这一点至关重要。本更新纳入KEYNOTE-522最终OS数据、GeparNuevo 7年随访数据及TORCHLIGHT III期数据,涵盖从新辅助至转移性疾病的全过程。 方法:我们检索了PubMed和ClinicalTrials.gov至2026年5月,以及会议论文集;Embase检索未发现额外试验。纳入的RCT比较了ICI联合化疗与单纯化疗在TNBC中的疗效,按疾病情境分层。主要终点为OS(转移性)和EFS/iDFS(早期阶段)。合并HR采用随机效应荟萃分析,并进行HKSJ校正。 结果:共10项RCT(5,953例患者)符合纳入标准。在转移性情境中(5项RCT,n = 3,526),ICI改善了OS(HR 0.85,95% CI 0.74-0.96;HKSJ校正后0.70-1.03;I² = 27%)和PFS(HR 0.82,0.73-0.92;I² = 35%);PD-L1+患者的OS获益更大(HR 0.79,0.65-0.95;I² = 51%)。抗PD-1对比抗PD-L1在数值上更大的OS获益在敏感性分析中不稳健。在早期阶段情境中(5项RCT,n = 2,427),ICI改善了EFS/iDFS(HR 0.75,0.63-0.90;I² = 0.2%)和OS(HR 0.64,0.53-0.78;I² = 0%)并提高了pCR(OR 1.65,1.39-1.98;I² = 1%)。HKSJ校正拓宽了CI,但效应模式保持一致。 结论:本更新证实了一致的生存 免疫检查点抑制剂(ICI)联合化疗在早期和转移性三阴性乳腺癌(TNBC)中均具有生存获益,且在PD-L1+人群中最为显著。长期数据显示疗效持久,尤其是在新辅助/辅助治疗背景下。白蛋白结合型紫杉醇与紫杉醇之间不同的结局凸显了化疗骨架的关键作用。这些发现支持现行指南,并强调需要更精细的生物标志物以将获益扩展至PD-L1阴性患者。 系统综述注册:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261356428,标识符CRD420261356428。
完整摘要 · 英文原文
BACKGROUND: Multiple RCTs have established PD-1/PD-L1 inhibitors as standard in triple-negative breast cancer (TNBC), but prior meta-analyses lacked complete setting coverage, mature long-term survival data, and a quantification of chemotherapy-backbone impact-critical given IMpassion130 (nab-paclitaxel, positive) vs. IMpassion131 (paclitaxel, negative). This update includes final KEYNOTE-522 OS, GeparNuevo 7-year follow-up, and TORCHLIGHT Phase III data, covering neoadjuvant to metastatic disease. METHODS: We searched PubMed and ClinicalTrials.gov to May 2026 plus conference proceedings; an Embase search found no additional trials. Included RCTs compared ICI + chemotherapy vs. chemotherapy alone in TNBC, stratified by setting. The primary endpoints are OS (metastatic) and EFS/iDFS (early-stage). Pooled HRs used random-effects meta-analysis with HKSJ adjustment. RESULTS: A total of 10 RCTs (5,953 patients) met the inclusion. In the metastatic setting (five RCTs, n = 3,526), ICI improved OS (HR 0.85, 95% CI 0.74-0.96; HKSJ-adjusted 0.70-1.03; I² = 27%) and PFS (HR 0.82, 0.73-0.92; I² = 35%); OS benefit was greater in PD-L1+ patients (HR 0.79, 0.65-0.95; I² = 51%). Numerically greater OS with anti-PD-1 vs. anti-PD-L1 was not robust in the sensitivity analysis. In the early-stage setting (five RCTs, n = 2,427), ICIs improved EFS/iDFS (HR 0.75, 0.63-0.90; I² = 0.2%) and OS (HR 0.64, 0.53-0.78; I² = 0%) and increased pCR (OR 1.65, 1.39-1.98; I² = 1%). HKSJ adjustment widened the Cis, but the effect patterns remained consistent. CONCLUSIONS: This update confirms a consistent survival benefit of ICI + chemotherapy in both early and metastatic TNBC, which was most pronounced in PD-L1+ populations. Long-term data show durability, especially in neoadjuvant/adjuvant settings. The divergent outcomes with nab-paclitaxel vs. paclitaxel underscore the critical role of the chemotherapy backbone. These findings support current guidelines and highlight the need for refined biomarkers to extend benefit to PD-L1-negative patients. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261356428, identifier CRD420261356428.
摘要 待译
BACKGROUND: Multiple RCTs have established PD-1/PD-L1 inhibitors as standard in triple-negative breast cancer (TNBC), but prior meta-analyses lacked complete setting coverage, mature long-term survival data, and a quantification of chemotherapy-backbone impact-critical given IMpassion130 (nab-paclitaxel, positive) vs. IMpassion131 (paclitaxel, negative). This update includes final KEYNOTE-522 OS, GeparNuevo 7-year follow-up, and TORCHLIGHT Phase III data, covering neoadjuvant to metastatic disease.…